AUSTIN, TEXAS - Austin-based
Ambion Inc.'s Diagnostic RNA unit has built
a new manufacturing lab and is seeking approval by the U.S. Food and Drug Administration to begin manufacturing products. Shifting its focus to the molecular pathology market, Ambion began the development in October 2000. The facility also houses space for devising disease test kit formulas.
<'xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
Printer Friendly Version
Send to a Friend
